Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Piramal Pharma's Other Stockholders Equity for the quarter that ended in Mar. 2026 was ₹13,752 Mil.
Piramal Pharma's quarterly Other Stockholders Equity
declined
from Sep. 2025 (₹67,483 Mil) to Dec. 2025 (₹0 Mil) but then
increased
from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹13,752 Mil).
Piramal Pharma's annual Other Stockholders Equity
increased
from Mar. 2024 (₹8,928 Mil) to Mar. 2025 (₹10,145 Mil) and
increased
from Mar. 2025 (₹10,145 Mil) to Mar. 2026 (₹13,752 Mil).
Piramal Pharma Other Stockholders Equity Related Terms
Piramal Pharma Other Stockholders Equity Historical Data
* Premium members only.
The historical data trend for Piramal Pharma's Other Stockholders Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Stockholders Equity of ₹13,752 Mil mean?
Piramal Pharma (NSE:PPLPHARMA) has a Other Stockholders Equity of ₹13,752 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Piramal Pharma and its competitors.
Is Piramal Pharma's Other Stockholders Equity too high?
Piramal Pharma's current Other Stockholders Equity is ₹13,752 Mil. Overall, Piramal Pharma has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Piramal Pharma's Other Stockholders Equity compare to ZTS and UTHR?
Piramal Pharma's Other Stockholders Equity of ₹13,752 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Piramal Pharma and its competitors. Piramal Pharma's current Other Stockholders Equity is ₹13,752 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Piramal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Piramal Pharma (NSE:PPLPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is ₹176.12, compared to a current price of ₹181.27 — trading 2.9% above its estimated fair value. The current Other Stockholders Equity is ₹13,752 Mil. Piramal Pharma's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Piramal Pharma (NSE:PPLPHARMA), the current Other Stockholders Equity is ₹13,752 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Piramal Pharma (NSE:PPLPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Piramal Pharma stock appears to be overvalued.
The current stock price of ₹181.27 is trading 2.9% above its estimated GF Value™ of ₹176.12.
GuruFocus considers Piramal Pharma to be Fairly Valued.
Key valuation signals for NSE:PPLPHARMA:
Other Stockholders Equity: ₹13,752 Mil
GF Value™: ₹176.12 vs. price of ₹181.27 (2.9% above fair value)
No single metric tells the full story. See the NSE:PPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
51GF Score
Get the complete analysis for NSE:PPLPHARMA
Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:PPLPHARMA has been successfully added to your 
